-
Expected FDA Approvals in the Second Half of 2025
01 Jul 2025 21:19 GMT
… drug FDA approvals. The list includes Attruby (acoramidis), which treats … developed to treat persistent or chronic immune thrombocytopenia (ITP) in adults. ITP … SEQUOIA-HCM phase 3 trial. The study randomly … for treating nrSPMS, for which there is no treatment. …
-
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
30 Jun 2025 12:16 GMT
… S. Food and Drug Administration (FDA) has approved GAMMAGARD … care teams to develop alternative treatment plans.”
About GAMMAGARD … patients receiving known nephrotoxic drugs. Renal dysfunction and … or distributed by Takeda Pharmaceutical Company Limited (“Takeda …
-
Biotech Stocks Facing FDA Decision In July 2025
29 Jun 2025 07:25 GMT
… drugs in the U.S. for treating … .42%.
Apellis Pharmaceuticals Inc. (APLS)
Apellis Pharma';s … intellectual disability, seizures, developmental delays, memory impairment, … drug Kuvan and injectable drug Palynziq are the two FDA-approved treatments …
-
Pfizer Gets CDSCO Panel Nod to Conduct Phase IIIb Trial of Rimegepant for Menstrual Migraine
28 Jun 2025 18:39 GMT
… related to treatment protocol during the trial:
“The prior medications shall be … the subject during the clinical trial.”
Rimegepant is an oral … countries for the acute treatment and preventive management of … Nod for Phase III Trial of IVIG in Chronic ITP
-
Tailoring Care in ITP Through a Health Equity Lens
27 Jun 2025 19:53 GMT
… ITP care requires open conversations about testing costs, insurance coverage, and treatment … accessibility, with clinicians helping patients navigate financial barriers through pharmaceutical assistance …
-
COVID Vaccine Side Effects: FDA Announces Rare Heart-Related Reactions - What You Should Know
27 Jun 2025 15:12 GMT
The US Food and Drug Administration (FDA) has released a new … labelling since 2021.
How FDA Determined the Side Effects
A … FDA back in 2024 looked at about 300 people who developed … .
Another is immune thrombocytopenia (ITP), a condition characterised by low …
-
Man, 24, breaks out in horror rash and risks bleeding to death after taking petrol station ‘Viagra’
02 Jul 2025 13:07 GMT
… a US hospital after developing unusual symptoms, including a … prescription Viagra used to treat erectile dysfunction.
" … The US Food and Drug Administration (FDA) has repeatedly warned … including antibiotics, anti-seizure drugs, and chemotherapy.
The man …
-
Risk Stratification for Cephalosporin-Induced Thrombocytopenia: Development and Validation of a Multidimensional Predictive Model in Older Adults
25 Jun 2025 01:22 GMT
… ITP) have provided relevant insights. Research has developed … treatment in hospitalized adults. Case ascertainment leveraged structured pharmacologic … drugs are used in combination with other medications, drug … with levofloxacin for treating community-acquired …
-
Aplastic Anemia Treatment Market Size In The 7MM Was ~USD 270 Million In 2023 And Is Further Expected To Increase By 2034, Estimates Delveinsight
12 Jun 2025 00:12 GMT
… or with medications to suppress … Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals and others. … a drug for idiopathic thrombocytopenic purpura (ITP) in … FDA-approved drugs for Aplastic Anemia @ Drugs for Aplastic Anemia Treatment …
-
Immune Thrombocytopenia at a Crossroads: New Therapies Aim to Replace Stopgap Treatments | Competitive Intelligence
10 Jun 2025 16:38 GMT
ITP affects 2–5/100k yearly. New therapies like BTK, FcRn blockers aim for lasting remission, fewer side effects, and may challenge injectable TPO-RA dominance.
AUSTIN, TX, UNITED STATES, June 10, 2025 /EINPresswire.com/ -- Immune …
About
© 1995-2025